Gianina Toller1, Yann Cobigo2, Peter A Ljubenkov2, Brian S Appleby3, Bradford C Dickerson4, Kimiko Domoto-Reilly5, Jamie C Fong2, Leah K Forsberg6, Ralitza H Gavrilova6, Nupur Ghoshal7, Hilary W Heuer2, David S Knopman6, John Kornak8, Maria I Lapid9, Irene Litvan10, Diane E Lucente4, Ian R Mckenzie11, Scott M McGinnis4, Bruce L Miller2, Otto Pedraza12, Julio C Rojas2, Adam M Staffaroni2, Bonnie Wong4, Zbigniew K Wszolek13, Brad F Boeve6, Adam L Boxer2, Howard J Rosen2, Katherine P Rankin2. 1. Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA gianina.toller@kssg.ch. 2. Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA. 3. Department of Neurology, Case Western Reserve University, Cleveland, OH, USA. 4. Department of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 5. Department of Neurology, University of Washington, Seattle, WA, USA. 6. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 7. Department of Neurology, Washington University, St. Louis, MO, USA. 8. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. 9. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. 10. Feinberg School of Medicine, Department of Neurology, Northwestern University, Chicago, IL, USA. 11. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 12. Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA. 13. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Abstract
BACKGROUND AND OBJECTIVES: Changes in social behavior are common symptoms of frontotemporal lobar degeneration (FTLD) and Alzheimer's disease syndromes. For early identification of individual patients and differential diagnosis, sensitive clinical measures are required that are able to assess patterns of behaviors and detect syndromic differences in both asymptomatic and symptomatic stages. We investigated whether the examiner-based Social Behavior Observer Checklist (SBOCL) is sensitive to early behavior changes and reflects disease severity within and between neurodegenerative syndromes. METHODS: Asymptomatic individuals and neurodegenerative disease patients were selected from the multisite ALLFTD cohort study. In a sample of participants with at least one timepoint of SBOCL data, we investigated whether the Disorganized, Reactive, and Insensitive subscales of the SBOCL change as a function of disease stage within and between these syndromes. In a longitudinal subsample with both SBOCL and neuroimaging data, we examined whether change over time on each subscale corresponds to progressive gray matter atrophy. RESULTS: 1082 FTLD mutation carriers and non-carriers were enrolled (282 asymptomatic, 341 behavioral variant frontotemporal dementia, 114 semantic and 95 non-fluent variant primary progressive aphasia, 137 progressive supranuclear palsy, 113 Alzheimer's clinical syndrome). The Disorganized score increased between asymptomatic to very mild (p=0.016, estimate=-1.10, 95%CI=[-1.99, -0.22]), very mild to mild (p=0.013, -1.17, [-2.08, -0.26]), and mild to moderate/severe (p<0.001, -2.00, [-2.55, -1.45]) disease stages in behavioral variant frontotemporal dementia regardless of mutation status. Asymptomatic GRN pathogenic gene variant carriers showed more Reactive behaviors (preoccupation with time: p=0.001, 1.11, [1.06, 1.16]; self-consciousness: p=0.003, 1.77, [1.52, 2.01]) than asymptomatic non-carriers (1.01, [0.98, 1.03]; 1.31, [1.20, 1.41]). Insensitive score increased to a clinically abnormal level in advanced stages of behavioral variant frontotemporal dementia (p=0.003, -0.73, [-1.18, -0.29]). Higher scores on each subscale corresponded with higher caregiver burden (p<0.001). Greater change over time corresponded to greater fronto-subcortical atrophy in the semantic-appraisal and fronto-parietal intrinsically connected networks. DISCUSSION: The SBOCL is sensitive to early symptoms and reflects disease severity, with some evidence for progression across asymptomatic and symptomatic stages of FTLD syndromes; thus it may hold promise for early measurement and monitoring of behavioral symptoms in clinical practice and treatment trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the Social Behavior Observer Checklist is sensitive to early behavioral changes in FTLD pathogenic variants and early symptomatic individuals in a highly educated patient cohort.
BACKGROUND AND OBJECTIVES: Changes in social behavior are common symptoms of frontotemporal lobar degeneration (FTLD) and Alzheimer's disease syndromes. For early identification of individual patients and differential diagnosis, sensitive clinical measures are required that are able to assess patterns of behaviors and detect syndromic differences in both asymptomatic and symptomatic stages. We investigated whether the examiner-based Social Behavior Observer Checklist (SBOCL) is sensitive to early behavior changes and reflects disease severity within and between neurodegenerative syndromes. METHODS: Asymptomatic individuals and neurodegenerative disease patients were selected from the multisite ALLFTD cohort study. In a sample of participants with at least one timepoint of SBOCL data, we investigated whether the Disorganized, Reactive, and Insensitive subscales of the SBOCL change as a function of disease stage within and between these syndromes. In a longitudinal subsample with both SBOCL and neuroimaging data, we examined whether change over time on each subscale corresponds to progressive gray matter atrophy. RESULTS: 1082 FTLD mutation carriers and non-carriers were enrolled (282 asymptomatic, 341 behavioral variant frontotemporal dementia, 114 semantic and 95 non-fluent variant primary progressive aphasia, 137 progressive supranuclear palsy, 113 Alzheimer's clinical syndrome). The Disorganized score increased between asymptomatic to very mild (p=0.016, estimate=-1.10, 95%CI=[-1.99, -0.22]), very mild to mild (p=0.013, -1.17, [-2.08, -0.26]), and mild to moderate/severe (p<0.001, -2.00, [-2.55, -1.45]) disease stages in behavioral variant frontotemporal dementia regardless of mutation status. Asymptomatic GRN pathogenic gene variant carriers showed more Reactive behaviors (preoccupation with time: p=0.001, 1.11, [1.06, 1.16]; self-consciousness: p=0.003, 1.77, [1.52, 2.01]) than asymptomatic non-carriers (1.01, [0.98, 1.03]; 1.31, [1.20, 1.41]). Insensitive score increased to a clinically abnormal level in advanced stages of behavioral variant frontotemporal dementia (p=0.003, -0.73, [-1.18, -0.29]). Higher scores on each subscale corresponded with higher caregiver burden (p<0.001). Greater change over time corresponded to greater fronto-subcortical atrophy in the semantic-appraisal and fronto-parietal intrinsically connected networks. DISCUSSION: The SBOCL is sensitive to early symptoms and reflects disease severity, with some evidence for progression across asymptomatic and symptomatic stages of FTLD syndromes; thus it may hold promise for early measurement and monitoring of behavioral symptoms in clinical practice and treatment trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the Social Behavior Observer Checklist is sensitive to early behavioral changes in FTLD pathogenic variants and early symptomatic individuals in a highly educated patient cohort.
Authors: M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman Journal: Neurology Date: 2011-02-16 Impact factor: 9.910
Authors: Casey L Brown; Sandy J Lwi; Madeleine S Goodkind; Katherine P Rankin; Jennifer Merrilees; Bruce L Miller; Robert W Levenson Journal: Am J Geriatr Psychiatry Date: 2017-12-27 Impact factor: 4.105
Authors: I Litvan; Y Agid; C Goetz; J Jankovic; G K Wenning; J P Brandel; E C Lai; M Verny; K Ray-Chaudhuri; A McKee; K Jellinger; R K Pearce; J J Bartko Journal: Neurology Date: 1997-01 Impact factor: 9.910
Authors: Winston Chiong; Stephen M Wilson; Mark D'Esposito; Andrew S Kayser; Scott N Grossman; Pardis Poorzand; William W Seeley; Bruce L Miller; Katherine P Rankin Journal: Brain Date: 2013-04-09 Impact factor: 13.501
Authors: Mario F Mendez; Sylvia S Fong; Jill S Shapira; Elvira E Jimenez; Natalie C Kaiser; Sarah A Kremen; Po-Heng Tsai Journal: Am J Alzheimers Dis Other Demen Date: 2013-12-26 Impact factor: 2.035
Authors: Jonathan D Rohrer; Jennifer M Nicholas; David M Cash; John van Swieten; Elise Dopper; Lize Jiskoot; Rick van Minkelen; Serge A Rombouts; M Jorge Cardoso; Shona Clegg; Miklos Espak; Simon Mead; David L Thomas; Enrico De Vita; Mario Masellis; Sandra E Black; Morris Freedman; Ron Keren; Bradley J MacIntosh; Ekaterina Rogaeva; David Tang-Wai; Maria Carmela Tartaglia; Robert Laforce; Fabrizio Tagliavini; Pietro Tiraboschi; Veronica Redaelli; Sara Prioni; Marina Grisoli; Barbara Borroni; Alessandro Padovani; Daniela Galimberti; Elio Scarpini; Andrea Arighi; Giorgio Fumagalli; James B Rowe; Ian Coyle-Gilchrist; Caroline Graff; Marie Fallström; Vesna Jelic; Anne Kinhult Ståhlbom; Christin Andersson; Håkan Thonberg; Lena Lilius; Giovanni B Frisoni; Michela Pievani; Martina Bocchetta; Luisa Benussi; Roberta Ghidoni; Elizabeth Finger; Sandro Sorbi; Benedetta Nacmias; Gemma Lombardi; Cristina Polito; Jason D Warren; Sebastien Ourselin; Nick C Fox; Martin N Rossor; Giuliano Binetti Journal: Lancet Neurol Date: 2015-02-04 Impact factor: 44.182
Authors: Suzee E Lee; Ana C Sias; Eena L Kosik; Taru M Flagan; Jersey Deng; Stephanie A Chu; Jesse A Brown; Anna A Vidovszky; Eliana Marisa Ramos; Maria Luisa Gorno-Tempini; Anna M Karydas; Giovanni Coppola; Daniel H Geschwind; Rosa Rademakers; Bradley F Boeve; Adam L Boxer; Howard J Rosen; Bruce L Miller; William W Seeley Journal: Neuroimage Clin Date: 2019-03-16 Impact factor: 4.881